SG11201909590XA - Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine - Google Patents

Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine

Info

Publication number
SG11201909590XA
SG11201909590XA SG11201909590XA SG11201909590XA SG 11201909590X A SG11201909590X A SG 11201909590XA SG 11201909590X A SG11201909590X A SG 11201909590XA SG 11201909590X A SG11201909590X A SG 11201909590XA
Authority
SG
Singapore
Prior art keywords
therapeutic agent
memantine
agent combining
dementia therapeutic
pyrazoloquinoline derivative
Prior art date
Application number
Inventor
Mai MIYAMOTO
Sadaharu Kotani
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of SG11201909590XA publication Critical patent/SG11201909590XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ABSfRACT There is provided a therapeutic agent for Alzheimer's disease for combined use of (S)-(2-methoxy-3,5-dimethylpyridin-4-y1)-1-(telmhydrofuran-3-y1)-1H-pyrazolo[4,3-c]qui noline-4(5H)-one represented by formula (1): 0 or a pharmaceutically acceptable salt thereof, and meniantine represented by formula (II): NH 2 ( H ) or a pharmaceutically acceptable salt thereof. 19
SG11201909590X 2017-06-01 2018-05-30 Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine SG11201909590XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762513754P 2017-06-01 2017-06-01
PCT/JP2018/020649 WO2018221550A1 (en) 2017-06-01 2018-05-30 Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine

Publications (1)

Publication Number Publication Date
SG11201909590XA true SG11201909590XA (en) 2019-11-28

Family

ID=64454745

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202113199RA SG10202113199RA (en) 2017-06-01 2018-05-30 Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
SG11201909590X SG11201909590XA (en) 2017-06-01 2018-05-30 Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202113199RA SG10202113199RA (en) 2017-06-01 2018-05-30 Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine

Country Status (12)

Country Link
US (1) US11147803B2 (en)
EP (1) EP3632437B1 (en)
JP (1) JP7177772B2 (en)
KR (1) KR102627790B1 (en)
CN (1) CN110603039B (en)
AU (1) AU2018276568A1 (en)
BR (1) BR112019023595A2 (en)
CA (1) CA3060183A1 (en)
IL (1) IL270394B (en)
MX (1) MX2019013383A (en)
SG (2) SG10202113199RA (en)
WO (1) WO2018221550A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202113198TA (en) 2017-06-01 2021-12-30 Eisai R&D Man Co Ltd Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
TWI784006B (en) 2017-06-01 2022-11-21 日商衛材R&D企管股份有限公司 Therapeutic agent for Lewis disease containing pyrazoloquinoline derivative
CN110545812A (en) 2017-06-01 2019-12-06 卫材R&D管理有限公司 Pharmaceutical compositions comprising PDE9 inhibitors
AU2022367432A1 (en) 2021-10-14 2024-05-02 Incyte Corporation Quinoline compounds as inhibitors of kras
CN114524827A (en) * 2022-02-22 2022-05-24 深圳市儿童医院 Pyrazole derivative for treating severe nervous disease and application thereof
CN114524828A (en) * 2022-02-22 2022-05-24 深圳市儿童医院 Thiazole derivative for treating severe nervous disease and application thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5318759A (en) 1976-08-02 1978-02-21 Nisshin Oil Mills Ltd Method of making fried beancurd
JPH05132484A (en) 1991-04-26 1993-05-28 Otsuka Pharmaceut Factory Inc Pyrazoloquinoline and pyrazolonaphthylidene derivative
BR9507672A (en) 1994-05-24 1997-08-19 Hoffmann La Roche Tricyclic derivatives of dicarbonyl
HN2002000317A (en) 2001-11-02 2003-05-21 Pfizer PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS
JP2005534713A (en) 2002-08-07 2005-11-17 三菱ウェルファーマ株式会社 Dihydropyrazolopyridine compounds
DE10238722A1 (en) 2002-08-23 2004-03-11 Bayer Ag Improving attention, concentration, cognition, learning and/or memory performance, using selective phosphodiesterase 9A inhibitors, preferably 4H-pyrazolo-(3,4-d)-pyrimidin-4-one derivatives
DE102004004142A1 (en) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines
RU2426734C2 (en) 2003-10-03 2011-08-20 Зм Инновейтив Пропертиз Компани Pyrazolopyridines and analogues thereof
WO2005118583A1 (en) 2004-05-28 2005-12-15 Millennium Pharmaceuticals, Inc. 2, 5-dihydro-pyrazolo`4, 3-c!quinolin-4-ones as chk-1 inhibitors
JP2006045118A (en) 2004-08-04 2006-02-16 Mochida Pharmaceut Co Ltd New pyrazoloquinolone derivative
CN101268073B (en) 2005-09-15 2011-10-19 Aska制药株式会社 Heterocyclic compound, and production process and use thereof
EP2489667B1 (en) 2006-12-13 2015-04-15 ASKA Pharmaceutical Co., Ltd. Quinoxaline derivative
KR20090097918A (en) 2006-12-13 2009-09-16 아스카 세이야쿠 가부시키가이샤 Therapeutic agent for urinary tract disease
JP4579346B2 (en) 2007-05-11 2010-11-10 ファイザー・インク Amino heterocyclic compounds
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
MX2011002340A (en) 2008-09-08 2011-04-04 Boehringer Ingelheim Int Pyrazolopyrimidines and their use for the treatment of cns disorders.
TWI404721B (en) 2009-01-26 2013-08-11 Pfizer Amino-heterocyclic compounds
JP5609861B2 (en) 2009-03-05 2014-10-22 アステラス製薬株式会社 Quinoxaline compounds
AP2011005819A0 (en) 2009-03-31 2011-08-31 Boehringer Ingelheim Int 1-heterocyclyl-1, 5-dihydropyrazolo[3,4-D] pyrimidin -4-one derivatives and their use as PDE9A modulators.
US8880976B2 (en) 2009-09-25 2014-11-04 Stmicroelectronics, Inc. Method and apparatus for encoding LBA information into the parity of a LDPC system
JP2012005157A (en) 2010-06-14 2012-01-05 Seiko Epson Corp Method of manufacturing laminated component
JP5756176B2 (en) 2010-08-12 2015-07-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 6-Cycloalkyl-1,5-dihydro-pyrazolo (3,4-D) pyrimidi-4-one derivatives and their use as PDE9A inhibitors
JP5888237B2 (en) 2010-09-07 2016-03-16 アステラス製薬株式会社 Pyrazoloquinoline compounds
US20130040971A1 (en) 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
EP2573073B1 (en) 2011-09-26 2014-10-22 Sanofi Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
JP6042060B2 (en) 2011-09-26 2016-12-14 サノフイ Pyrazoloquinolinone derivatives, their preparation and therapeutic use
WO2013051639A1 (en) * 2011-10-07 2013-04-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 Pyrazoloquinoline derivative
CN105121440B (en) * 2013-04-05 2017-05-24 卫材R&D管理有限公司 Salt of pyrazoloquinoline derivative, and crystal thereof
CN110545812A (en) 2017-06-01 2019-12-06 卫材R&D管理有限公司 Pharmaceutical compositions comprising PDE9 inhibitors
TWI784006B (en) 2017-06-01 2022-11-21 日商衛材R&D企管股份有限公司 Therapeutic agent for Lewis disease containing pyrazoloquinoline derivative
SG10202113198TA (en) 2017-06-01 2021-12-30 Eisai R&D Man Co Ltd Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
CN108563565B (en) 2018-04-08 2021-12-17 中国人民解放军海军工程大学 Method for establishing reliability quantitative analysis model of flight landing guidance system

Also Published As

Publication number Publication date
KR20200010219A (en) 2020-01-30
RU2019135838A (en) 2021-07-13
KR102627790B1 (en) 2024-01-23
US11147803B2 (en) 2021-10-19
US20200129488A1 (en) 2020-04-30
MX2019013383A (en) 2020-02-20
SG10202113199RA (en) 2021-12-30
IL270394B (en) 2022-08-01
EP3632437B1 (en) 2024-03-13
JP7177772B2 (en) 2022-11-24
CA3060183A1 (en) 2018-12-06
EP3632437A1 (en) 2020-04-08
BR112019023595A2 (en) 2020-05-26
IL270394A (en) 2020-02-27
AU2018276568A1 (en) 2019-11-07
RU2019135838A3 (en) 2021-09-29
EP3632437A4 (en) 2021-03-17
CN110603039A (en) 2019-12-20
WO2018221550A1 (en) 2018-12-06
JPWO2018221550A1 (en) 2020-04-02
CN110603039B (en) 2023-02-28

Similar Documents

Publication Publication Date Title
SG11201909590XA (en) Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
SG11201909595VA (en) Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
JOP20190076B1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
MX2022000244A (en) PYRROLO [2, 3-b] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF.
PH12019500776A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
NZ766835A (en) Pharmaceutical compounds
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MX2019013397A (en) Lewy body disease therapeutic agent containing pyrazoloquinoline derivative.
PL1663244T3 (en) Pteridine derivatives for the treatment of tnf-alpha-related diseases.
MX2018012211A (en) Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders.
MX2019006612A (en) IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS.
JOP20190233A1 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
MX2018012208A (en) Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders.
PH12020550168A1 (en) Griseofulvin compound and pharmaceutical use thereof
MX2021010122A (en) Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders.
MX2020002630A (en) IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS.
MX2019013198A (en) Pharmaceutical composition comprising pde9 inhibitor.
MX2021007247A (en) Rapamycin derivatives.
MX2023001071A (en) Treatment of migraine.
SA519401827B1 (en) Pyrido[3,4-D]Pyrimidine Derivative and Pharmaceutically Acceptable Salt Thereof
MX2018011592A (en) Compound having mutant idh inhibitory activity, preparation method and use thereof.
MX2019004602A (en) Anti-proliferative agents for treating pah.
PH12020551772A1 (en) Oxo-substituted compound
ZA202200331B (en) Naltrexone formulation
MX2022000729A (en) Combination therapy for cancer treatment.